Universal Beteiligungs und Servicegesellschaft mbH Has $4.18 Million Position in Alkermes plc $ALKS

Universal Beteiligungs und Servicegesellschaft mbH grew its position in Alkermes plc (NASDAQ:ALKS) by 12.5% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 139,166 shares of the company’s stock after purchasing an additional 15,501 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Alkermes were worth $4,175,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Royal Bank of Canada lifted its holdings in Alkermes by 117.2% during the 1st quarter. Royal Bank of Canada now owns 275,526 shares of the company’s stock valued at $9,098,000 after purchasing an additional 148,696 shares during the last quarter. Ashton Thomas Private Wealth LLC bought a new position in shares of Alkermes in the first quarter valued at approximately $213,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Alkermes by 4.3% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 482,332 shares of the company’s stock worth $15,927,000 after acquiring an additional 20,091 shares in the last quarter. Public Employees Retirement System of Ohio boosted its holdings in shares of Alkermes by 480.6% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 4,418 shares of the company’s stock worth $126,000 after acquiring an additional 3,657 shares in the last quarter. Finally, State of Alaska Department of Revenue grew its position in Alkermes by 9.0% during the 2nd quarter. State of Alaska Department of Revenue now owns 98,173 shares of the company’s stock worth $2,808,000 after acquiring an additional 8,070 shares during the last quarter. Institutional investors own 95.21% of the company’s stock.

Insider Activity

In related news, EVP Craig C. Hopkinson sold 5,000 shares of the firm’s stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $30.00, for a total value of $150,000.00. Following the transaction, the executive vice president owned 61,740 shares in the company, valued at approximately $1,852,200. This trade represents a 7.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last quarter, insiders sold 25,748 shares of company stock worth $765,060. Corporate insiders own 4.40% of the company’s stock.

Alkermes Trading Up 1.2%

NASDAQ ALKS opened at $33.52 on Wednesday. The company has a market cap of $5.53 billion, a price-to-earnings ratio of 16.59 and a beta of 0.48. The company has a 50 day moving average of $29.48 and a 200-day moving average of $29.28. Alkermes plc has a 1-year low of $25.17 and a 1-year high of $36.45.

Alkermes (NASDAQ:ALKS) last posted its quarterly earnings data on Tuesday, October 28th. The company reported $0.49 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.08. The firm had revenue of $394.19 million for the quarter, compared to analyst estimates of $355.23 million. Alkermes had a return on equity of 21.81% and a net margin of 22.27%.The company’s revenue was up 4.3% on a year-over-year basis. During the same quarter last year, the company earned $0.73 EPS. On average, equities research analysts forecast that Alkermes plc will post 1.31 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on ALKS shares. Weiss Ratings reiterated a “hold (c+)” rating on shares of Alkermes in a research report on Monday, December 29th. Zacks Research upgraded Alkermes from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 13th. Mizuho upped their price target on shares of Alkermes from $40.00 to $45.00 and gave the stock an “outperform” rating in a research report on Monday, October 27th. Needham & Company LLC increased their price objective on shares of Alkermes from $43.00 to $44.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Finally, Jefferies Financial Group set a $56.00 target price on shares of Alkermes and gave the stock a “buy” rating in a research note on Tuesday, October 28th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $44.69.

Alkermes Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.